fda halts glp-1 Compounders protest as removes tirzepatide off shortage list Compounded" GLP-1 drugs | Health

The Accessibility Challenge in Weight Loss Treatment For years, individuals struggling with obesity have faced multiple obstacles in accessing medical-grade weight loss solutions: Prohibitive costs: Branded GLP-1 medications can exceed $1,000-$1,300 monthly without insurance coverage Insurance hurdles: Many plans exclude weight loss medications or require extensive prior authorization processes Limited provider access: Specialists may have months-long waitlists Geographic barriers: Quality weight management clinics may not exist in rural or underserved areas Time constraints: Traditional appointments require time off work and commuting Telehealth platforms like Freya Meds address these challenges by leveraging technology, compounded medications, and direct-to-consumer models that prioritize convenience and transparency

Patients often experience more stable energy, improved digestion, better sleep, reduced inflammation, and enhanced overall metabolic health

Semaglutide represents the most widely discussed GLP-1 receptor agonist for weight management

Han, Y., Li, Y